In its quarterly filing with the Securities and Exchange Commission, Boston Scientific Corp. revealed that it had received a subpoena from the U.S. Attorney for the District of New Jersey on July 11, The Wall Street Journal reports.
“The subpoena seeks information relating to BridgePoint Medical, Inc., which we acquired in October 2012, including information relating to its sale of CrossBoss and Stingray products, educational and training activities related to those sales and our acquisition of BridgePoint Medical,” Boston Scientific’s Form 10-Q reads. “We are cooperating with this request.”
Boston Scientific is a medical device maker, which competes against several companies, including Medtronic Inc. and St. Jude Medical Inc. in the sale of heart devices. The industry has faced increased scrutiny over the past few years in connection with the way incentives are used to gain market share, The Wall Street Journal reports.
In a regulatory filing in May, Boston Scientific revealed that it had received a subpoena from the Department of Health and Human Services seeking information related to the 2008 launch of two brands of implanted cardioverter defibrillators, which are used to treat arrhythmias by shocking the heart back into a normal rhythm, Reuters reported at the time.
In October 2013 Boston Scientific agreed to pay $30 million to settle Department of Justice allegations that the Guidant unit, acquired by the company in 2006, knowingly sold defective heart devices that were implanted in Medicare patients, according to Reuters.